Custom Antibody Development
Our custom antibody development services utilize state-of-the-art phage-display technology to generate highly specific and sensitive antibodies tailored to meet your research needs. With our expertise in antibody engineering, we can design and produce antibodies against a wide range of targets, including proteins and peptides.
Sequence-Based Optimization for Enhanced Antibody Expression
Our sequence-based optimization service is designed to boost antibody expression rates. Through detailed analysis of the antibody’s amino acid sequence, we identify and target specific regions for enhancement, maximizing both its functionality and production yield. This comprehensive approach integrates advanced structure analysis, precise antibody framework engineering, and the proven efficiency of phage-display screening. Combined, these methodologies not only elevate antibody expression but also ensure optimal performance in subsequent applications.
Maturation of Binding Affinity
Harnessing the precision of structure-guided optimization, we determine critical regions in antibodies, offering a strategic advantage over traditional techniques. Our in-depth comprehension of the intricate molecular interactions between antibodies and antigens allows for precise modifications, ensuring that the matured antibodies exhibit enhanced affinity while retaining their specificity.
To further bolster this process, we employ the cutting-edge phage-display technology. This method facilitates the generation and screening of expansive antibody variant libraries, emphasizing the selection of those with the utmost affinity. Through successive rounds of this selection process, we refine and perfect, guaranteeing that the resulting antibodies represent the pinnacle of precision and potency, ready for advanced research and applications.
Antibody Humanization
Antibody humanization is a cornerstone in the progression of therapeutic antibodies. It ensures that antibodies originally derived from non-human sources are adapted for optimal efficacy and reduced immunogenicity in human applications. Two prominent methods we employ for this purpose are CDR-grafting and full humanization.
CDR-grafting: Merging Mouse Specificity with Human Framework
At the heart of the CDR-grafting technique lies the transfer of Complementarity-Determining Regions (CDRs) from a mouse antibody onto a human antibody framework. These CDRs, which are instrumental in binding to antigens, retain the affinity and specificity of the original mouse-derived antibody. However, simple grafting can sometimes disturb the original binding properties. To tackle this, we integrate strategic back mutations. This ensures that the humanized antibody retains its original binding prowess, providing a product that is both effective and human-compatible.
Fully-Humanized Antibodies: Total Human Derivation with Precision Binding
Our full-humanization method takes a different approach. Rather than grafting mouse-derived CDRs onto a human framework, we screen for both the human light chain and heavy chain from an extensive human library using phage-display technology. This ensures that the resultant antibody is entirely derived from human sequences. However, guaranteeing specificity is equally crucial. To confirm that our fully humanized antibody recognizes and binds to the same epitope as the original, we employ a rigorous triple-verification process. This rigorous approach guarantees that the final antibody maintains its target specificity while being entirely human in origin, ensuring optimal therapeutic potential with minimized immunogenicity.